Skip to main content

Obelisk Project

We believe the most effective way to prevent a high prevalence of obesity throughout the life course is to avoid its development in children and promote healthy weight maintenance during adolescence and young adulthood.


The main concept behind Obelisk, is dedicated to understanding, predicting, and preventing obesity in children and providing precision medicine for those affected.

The 4P’s approach of Obelisk involves active participation from all stakeholders including families, scientific and medical communities, daycare centres, schools, policymakers, and industry, to drive social innovation and achieve successful outcomes.

Obelisk 4P's Approach


Our ambitious research programme will be implemented over five years by a consortium of 15 partners across Europe. The programme is based on the 4P approach. It aims to develop evidence-based clinical guidelines, best practices, and preventive strategies to combat overweight and obesity and their associated health conditions at all stages of life.

With the help of predictive tools and targeted prevention strategies developed by Obelisk, patients and clinicians can work together to make informed decisions on the most suitable interventions for controlling the progression of obesity in children. This empowers patients to take control of their health and well-being.

By following the Obelisk evidence-based guidelines, policymakers, national and local authorities, nurseries, schools, and sports centres can create more efficient prevention campaigns to combat childhood overweight and obesity.


Increase the implementation of successful preventive and treatment programs in clinics and communities.
Decrease the rates of childhood obesity across the EU.
Increase the percentage of children and adolescents with obesity who successfully receive treatment and recover from obesity before adulthood.

Improve health and quality of life for children and adolescents living with obesity.

Families of children at risk for obesity or who already have obesity can benefit from reduced economic burden through preventative measures and treatment options.
The evaluation of semaglutide in real-life scenarios may lead to the development of promising new medications, including dual GIP/GLP1 receptor agonists, for common types of early-onset obesity accompanied by appetite dysregulation.